. 2020 Jul 7;10(7):e038430. doi: 10.1136/bmjopen-2020-038430

Table 1.

Inclusion and exclusion criteria

Inclusion criteria	Exclusion criteria
Adults >18 years Diagnosis of current MDD (defined according to the DSM-5), that is, treatment-resistant defined as scoring 2 or more on the Massachusetts General Hospital Treatment Resistant Depression staging score (online supplementary appendix 1). Have a 17-Item Hamilton Depression Rating Scale score of 16 or more (moderate to severe depression). Capacity to provide informed consent before any trial related activities.	History of bipolar disorder (due to risk of mania) or depression secondary to other mental disorder. Neurological conditions, for example, brain neoplasm, cerebrovascular events, epilepsy, neurodegenerative disorders and prior brain surgery. Standard contraindications to MRI, that is, irremovable metal objects in and around body, for example, cardiac pacemaker, implanted medication pump, and pregnancy (any doubt resolved by pregnancy test, women of childbearing age taking precautions against pregnancy). This will include other potential complicated factors such as red tattoos which consist of iron on the head, neck and back and claustrophobia (we offer mock scanner testing and training in some sites). Major unstable medical illness requiring further investigation or treatment. Change in prescribed medication 2 weeks before baseline assessment. Prescription of lamotrigine, gabapentin, pregabalin in the 2 weeks prior to baseline assessment but may be used before then. Daily prescription of benzodiazepine above 5 mg diazepam equivalents, zopiclone above 7.5 mg, zolpidem above 10 mg or Zaleplon above 10 mg. These drugs should not be used intermittently in the 2 weeks before baseline assessment but may be used before then. Current substance abuse or dependence (defined by DSM-5 criteria). Prior TMS treatment. At risk of suicidality. Potential complicated factors relating to the TMS treatment, that is, hairstyles which would impair magnetic transmission and piercings. (Participants would only be excluded if they chose to not make the changes required to ensure effective treatment.) Involved with any other clinical trial at the time of consent or 6 months prior. Unable to read or understand English.

Inclusion criteria

Exclusion criteria

Adults >18 years
Diagnosis of current MDD (defined according to the DSM-5), that is, treatment-resistant defined as scoring 2 or more on the Massachusetts General Hospital Treatment Resistant Depression staging score (online supplementary appendix 1).
Have a 17-Item Hamilton Depression Rating Scale score of 16 or more (moderate to severe depression).
Capacity to provide informed consent before any trial related activities.

History of bipolar disorder (due to risk of mania) or depression secondary to other mental disorder.
Neurological conditions, for example, brain neoplasm, cerebrovascular events, epilepsy, neurodegenerative disorders and prior brain surgery.
Standard contraindications to MRI, that is, irremovable metal objects in and around body, for example, cardiac pacemaker, implanted medication pump, and pregnancy (any doubt resolved by pregnancy test, women of childbearing age taking precautions against pregnancy). This will include other potential complicated factors such as red tattoos which consist of iron on the head, neck and back and claustrophobia (we offer mock scanner testing and training in some sites).
Major unstable medical illness requiring further investigation or treatment.
Change in prescribed medication 2 weeks before baseline assessment.
Prescription of lamotrigine, gabapentin, pregabalin in the 2 weeks prior to baseline assessment but may be used before then.
Daily prescription of benzodiazepine above 5 mg diazepam equivalents, zopiclone above 7.5 mg, zolpidem above 10 mg or Zaleplon above 10 mg. These drugs should not be used intermittently in the 2 weeks before baseline assessment but may be used before then.
Current substance abuse or dependence (defined by DSM-5 criteria).
Prior TMS treatment.
At risk of suicidality.
Potential complicated factors relating to the TMS treatment, that is, hairstyles which would impair magnetic transmission and piercings. (Participants would only be excluded if they chose to not make the changes required to ensure effective treatment.)
Involved with any other clinical trial at the time of consent or 6 months prior.
Unable to read or understand English.

DSM-5, Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition; MDD, major depressive disorder; TMS, transcranial magnetic stimulation.